pdl1抑制剂说明书_pd%2dl1_pdl1(3)

NO SERIOUS SIDE EFFECTS SEEN

MPDL3280A, which was administered intravenously every three weeks, attacks a different target than a similar class of highly promising immunotherapies called PD-1 inhibitors being developed by Bristol-Myers Squibb, Merck & Co and others.

Roche and some researchers believe the anti-PDL1 medicine is more selective than the PD-1 drugs and may lead to less inflammation of the lung and other organs.

The Roche drug was well tolerated in the study, Herbst said: There were no side effects that required limiting the dosing.

"Most of the adverse events were transient and of low significance. We haven't seen any patients with significant inflammation of lung," said Herbst, chief of medical oncology at Yale Cancer Center in New Haven, Connecticut.

The data on progression-free survival, or the average time before a cancer begins to worsen, was not yet complete, and it will be a while before an overall survival benefit can be determined. But Herbst found the results thus far compelling.

"The progression-free survival for refractory lung, melanoma and renal cancers is impressive compared to historical controls," he said. "This is an incredibly interesting approach for cancer. It's showing efficacy. We're still learning how to select the patients properly."

Toward that end Roche is developing a diagnostic tool to identify those most likely to benefit from the treatment, such as those who test positive for the PDL1 protein.

Based on the trial's results, Roche said it will begin a larger study of its anti-PDL1 drug in patients with non-small-cell lung cancer that could be used to seek approval of the medicine.